|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Erlotinib versuschemotherapy (CT) in advanced non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemo-therapy (EURTAC) phase III randomized trial 显示文摘 | Rosell R Gervais R Vergnenegre A | 2011 | J Clin Oncol2011，29，15： | 1 |
| 2 | Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations:interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase Ⅲ randomized trial显示文摘 | Rosell R Gervais R Vergnenegre A | | 0，，： | 1 |
| 3 | Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial显示文摘 | Rafael Rosell Enric Carcereny Radj Gervais Alain Vergnenegre Bartomeu Massuti Enriqueta Felip Ramon Palmero Ramon Garcia-Gomez Cinta Pallares Jose Miguel Sanchez Rut Porta Manuel Cobo Pilar Garrido Flavia Longo Teresa Moran Amelia Insa Filippo De Marinis | 2012 | Lancet Oncology2012，，3： | 1 |
| 4 | Second - line therapy for NSCLC in clinical practice: baseline results of the European SELECTTION observational study显示文摘 | Moro- Sibilot D Vergnenegre A Smit E F | 2010 | Curt Med Res Opin2010，26，11： | 1 |
| 5 | Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations:interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase Ⅲ randomized trial显示文摘 | Rosell R Gervais AR Vergnenegre B | 2011 | J Clin Oncol2011，，： | 1 |
| 6 | Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial显示文摘 | Rafael Rosell Enric Carcereny Radj Gervais Alain Vergnenegre Bartomeu Massuti Enriqueta Felip Ramon Palmero Ramon Garcia-Gomez Cinta Pallares Jose Miguel Sanchez Rut Porta Manuel Cobo Pilar Garrido Flavia Longo Teresa Moran Amelia Insa Filippo De Marinis | 2012 | Lancet Oncology2012，，3： | 1 |
| 7 | Second- line therapy for NSCLC in clinical practice: baseline re- sults of the European SELECTTION observational study 显示文摘 | Moro-Sibilot D Vergnenegre A Smit EF | 2010 | Curr Med Res Opin2010，26，11： | 1 |
| 8 | Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial显示文摘 | Rafael Rosell Enric Carcereny Radj Gervais Alain Vergnenegre Bartomeu Massuti Enriqueta Felip Ramon Palmero Ramon Garcia-Gomez Cinta Pallares Jose Miguel Sanchez Rut Porta Manuel Cobo Pilar Garrido Flavia Longo Teresa Moran Amelia Insa Filippo De Marinis | 2012 | Lancet Oncology2012，，3： | 1 |
| 9 | Erlotinib versus chemotherapy (CT) inadvanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growthfactr receptor (EGFR) mutations Interim results of the European Erlotinib VersusChemotherapy (EURTAC) phase III randomized trial 显示文摘 | Rosell R Gervais R Vergnenegre A | 2011 | J Clin Oncol2011，22，10： | 1 |
| 10 | Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations:Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase Ⅲ randomized trial显示文摘 | Rosell R Gervais R Vergnenegre A | | 0，，： | 1 |
| 11 | Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial显示文摘 | Rafael Rosell Enric Carcereny Radj Gervais Alain Vergnenegre Bartomeu Massuti Enriqueta Felip Ramon Palmero Ramon Garcia-Gomez Cinta Pallares Jose Miguel Sanchez Rut Porta Manuel Cobo Pilar Garrido Flavia Longo Teresa Moran Amelia Insa Filippo De Marinis | 2012 | Lancet Oncology2012，，3： | 1 |
| 12 | Second-line therapy for NSCLC in clinical practice:baseline results of the European SELECTTION observational study显示文摘 | Moro-Sibilot D Vergnenegre A Smit EF | | 0，，11： | 1 |
| 13 | Epidemiology of distal humerus fractures in the elder|y显示文摘 | Charissoux JL Vergnenegre G Pelissier M | 2013 | Orthop Trauma Surg Res2013，99，7： | 1 |
| 14 | Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer(NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations : Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) Phase Ⅲ Randomized Trial 显示文摘 | Rosell R Gervais R Vergnenegre A | 2011 | J Clin Oncol2011，29，15： | 1 |
| 15 | Second-line therapy for NSCLC in clinical practice: baseline results of the European SE LECTTION observational study显示文摘 | Moro-Sibilot D Vergnenegre A Smit E F | 2010 | Curr Med Res Opin2010，26，11： | 1 |
| 16 | Biomarkers in lung oncology显示文摘 | Rosell R Vergnenegre A Liu B | 2010 | Pulm Pharmacol Ther2010，23，6： | 1 |
| 17 | Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial显示文摘 | Rafael Rosell Enric Carcereny Radj Gervais Alain Vergnenegre Bartomeu Massuti Enriqueta Felip Ramon Palmero Ramon Garcia-Gomez Cinta Pallares Jose Miguel Sanchez Rut Porta Manuel Cobo Pilar Garrido Flavia Longo Teresa Moran Amelia Insa Filippo De Marinis | 2012 | Lancet Oncology2012，，3： | 1 |
| 18 | Crossmarket cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer显示文摘 | VERGNENEGRE A RAY JA CHOUAID C | 2012 | Clinicoecon Outcomes Res2012，4，： | 1 |
| 19 | Erlotinib versus chemotherapy( CT) in advanced non-small cell lung cancer ( NSCLC ) patients (p) with epidermal growth factor receptor (EGFR) mutations :Interim results of the European Erlotin- ib Versus Chemotherapy(EURTAC) phase III randomized trial显示文摘 | Rosell R Gervais R Vergnenegre A | 2011 | J Clin Onco2011，29，3： | 1 |
| 20 | Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, malticenter phase 111 trial comparing docetaxel and pemetrexed: the GFPC 054)6 study 显示文摘 | VERGNENEGRE A CORRE R BERARD H | 2011 | J Thorac Oncol2011，6，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员